Compare Snap Inc (SNAP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs Zimmer Biomet Holdings Inc — how do they compare? Snap Inc trades at $5.91 (market cap $9.83B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Snap Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Snap Inc for 68 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SNAP | ZBH | |
|---|---|---|
Market Cap | $9.83B | $16.95B |
Volume | 28,532,342 | 2,505,240 |
Sector | Media | Health |
52-Week High | $9.09 | $103.98 |
52-Week Low | $3.93 | $79.58 |
Typical Hold Time | 68 Days | 89 Days |
Enterprise Value | $11.39B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $5.81, up 0.17% with a bullish technical signal. The company shows improving fundamentals with revenue growth to $5.93B in 2025 and narrowing losses (-$460M vs -$1.4B in 2022). Recent news highlights AI integration in SPECS glasses with NVIDIA and Salesforce partnerships. Analyst consensus is mixed with 38% buy ratings and $7.78 price target, representing 34% upside potential.
Snap presents a turnaround story with improving financials but remains unprofitable. The stock offers potential upside from AI initiatives and revenue growth, balanced by competitive pressures and regulatory risks. Current valuation at 1.55 P/S appears reasonable for the growth trajectory, though profitability remains the key hurdle for sustained gains.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
